Tag: Mydecine - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Post published:February 24, 2021
Post category:Press Release

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology

Post published:February 17, 2021
Post category:Press Release

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

Post published:February 12, 2021
Post category:Press Release

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

Post published:February 3, 2021
Post category:Press Release

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

Post published:February 1, 2021
Post category:Press Release

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

Post published:January 28, 2021
Post category:Press Release

Mydecine Innovations Group Files Application to list to the NASDAQ

Mydecine Innovations Group Files Application to list to the NASDAQ

Post published:January 27, 2021
Post category:Press Release

Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units

Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units

Post published:January 21, 2021
Post category:Press Release

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Post published:January 14, 2021
Post category:Press Release

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

Post published:January 11, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.